Query: Small-molecule modulators AND myotube contractile dysfunction in Inclusion Body Myositis AND restoration of sarcomere function in patient-derived skeletal muscle cells AND evidence of on-target engagement AND data on ADME and toxicity

Based on the comprehensive analysis of the provided context, there is currently no evidence in the literature that meets all the criteria regarding small-molecule modulators that correct myotube contractile dysfunction and restore sarcomere function in Inclusion Body Myositis (IBM) patient‐derived skeletal muscle cells, with demonstrated on‑target engagement and established ADME/toxicity profiles.

First, clinical trial searches (Clinical Trials Search: small-molecule modulator AND Inclusion Body Myositis AND skeletal muscle contraction) have returned zero results. This absence of registered trials directly targeting IBM with small-molecule modulators indicates that no compounds have reached a stage where their ability to correct myotube contractile dysfunction or restore sarcomere function has been confirmed in clinical settings (Clinical Trials Search: small-molecule modulator AND Inclusion Body Myositis AND skeletal muscle contraction).

Second, target association platforms such as Open Targets identify genes like GNE and MYH2 as relevant for IBM pathology based on genetic association data but do not curate any associated small molecules that act on these targets in a manner that improves sarcomere function or muscle contractility. There is no documented evidence regarding the restoration of contractile function, nor are there data on the mechanism of on‑target engagement or ADME/toxicity profiling for hypothetical modulators targeting these genes (OpenTargets Search: Inclusion Body Myositis).

Third, several in‑vitro studies and reviews (e.g., mccord2023investigatingtheinfluence pages 235-238 and mccord2023investigatingtheinfluencea pages 235-238) detail the investigation of molecular features of IBM, including the role of inflammatory mediators and TDP-43 pathology. However, these works repeatedly emphasize the lack of small-molecule candidates that can functionally reverse the contractile deficits or restore sarcomere integrity in patient-derived skeletal muscle cells. There is no mention of compounds that have progressed to pharmacological validation steps involving direct demonstration of on‑target engagement, nor is there data presented on ADME/toxicity for such modulators in the context of IBM (mccord2023investigatingtheinfluence pages 235-238, mccord2023investigatingtheinfluencea pages 235-238).

Similarly, reviews that address therapeutic strategies for muscle diseases (zschuntzsch2022theevolutionof pages 22-23, rawls2023pharmacotherapeuticapproachesto pages 22-23) consistently note that while various compounds (mostly biologics or immunomodulators) have been explored for inflammatory myopathies and related muscular dystrophies, there remains a gap in evidence for small-molecule interventions specifically aimed at correcting the contractile dysfunction or restoring the sarcomeric structure in IBM. The research emphases in these reviews are typically on alternative pathways such as immunomodulation, myostatin inhibition, or calcium handling modulation in dystrophies—and not on the detailed molecular correction of sarcomere function with supportive ADME/toxicity profiles (zschuntzsch2022theevolutionof pages 22-23, rawls2023pharmacotherapeuticapproachesto pages 22-23).

Moreover, while studies in other muscle pathologies, such as Duchenne Muscular Dystrophy, have demonstrated that small molecules like RyR modulators or utrophin upregulators can improve muscle function with evidence of on‑target engagement and some pharmacokinetic data (aristizabal2017effectofnovel pages 155-160, babbs20202arylbenzo[d]oxazolephosphinateesters pages 1-5), there is no cross‐over evidence that these or similar compounds have been applied or validated in IBM patient-derived skeletal muscle cells (aristizabal2017effectofnovel pages 155-160).

In summary, while innovative muscle disease models and various pharmacological approaches are actively researched, the specific small-molecule modulators that fulfill all outlined criteria for IBM—namely, correction of myotube contractile dysfunction, restoration of sarcomere function, evidence of on-target engagement, and detailed ADME/toxicity profiles—have not been documented in the current literature (Clinical Trials Search: small-molecule modulator AND Inclusion Body Myositis AND skeletal muscle contraction, OpenTargets Search: Inclusion Body Myositis, mccord2023investigatingtheinfluence pages 235-238, zschuntzsch2022theevolutionof pages 22-23).

References:
1. (OpenTargets Search: Inclusion Body Myositis): Open Targets Query (Inclusion Body Myositis, 13 results). Ochoa, D. et al. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Research.

2. (mccord2023investigatingtheinfluence pages 235-238): B McCord. Investigating the influence of inflammatory mediators on non-inflammatory features of sporadic inclusion body myositis in vitro. Unknown journal, 2023.

3. (mccord2023investigatingtheinfluencea pages 235-238): B McCord. Investigating the influence of inflammatory mediators on non-inflammatory features of sporadic inclusion body myositis in vitro. Unknown journal, 2023.

4. (zschuntzsch2022theevolutionof pages 22-23): Jana Zschüntzsch, Stefanie Meyer, Mina Shahriyari, Karsten Kummer, Matthias Schmidt, Susann Kummer, and Malte Tiburcy. The evolution of complex muscle cell in vitro models to study pathomechanisms and drug development of neuromuscular disease. Cells, 11:1233, Apr 2022. URL: https://doi.org/10.3390/cells11071233, doi:10.3390/cells11071233. This article has 12 citations and is from a peer-reviewed journal.

5. (aristizabal2017effectofnovel pages 155-160): GA Aristizabal. Effect of novel ryanodine receptor modulators in mouse and human models of duchenne muscular dystrophy. Unknown journal, 2017.

6. (rawls2023pharmacotherapeuticapproachesto pages 22-23): Alan Rawls, Bridget K. Diviak, Cameron I. Smith, Grant W. Severson, Sofia A. Acosta, and Jeanne Wilson-Rawls. Pharmacotherapeutic approaches to treatment of muscular dystrophies. Biomolecules, 13:1536, Oct 2023. URL: https://doi.org/10.3390/biom13101536, doi:10.3390/biom13101536. This article has 10 citations and is from a peer-reviewed journal.

7. (babbs20202arylbenzo[d]oxazolephosphinateesters pages 1-5): Arran Babbs, Adam Berg, Maria Chatzopoulou, Kay E. Davies, Stephen G. Davies, Benjamin Edwards, David J. Elsey, Enrico Emer, Simon Guiraud, Shawn Harriman, Cristina Lecci, Lee Moir, David Peters, Neil Robinson, Jessica A. Rowley, Angela J. Russell, Sarah E. Squire, Jonathon M. Tinsley, Francis X. Wilson, and Graham M. Wynne. 2-arylbenzo[<i>d</i>]oxazole phosphinate esters as second-generation modulators of utrophin for the treatment of duchenne muscular dystrophy. Journal of Medicinal Chemistry, 63:7880-7891, Jun 2020. URL: https://doi.org/10.1021/acs.jmedchem.0c00807, doi:10.1021/acs.jmedchem.0c00807. This article has 23 citations and is from a highest quality peer-reviewed journal.
